Reassess the choice of "non-oncology" drugs used to treat co-morbidities in their patients who have also been diagnosed with cancer.
Understand drugs with short-term benefits for cancer patients (e.g. dexamethasone used vs glioblastoma brain swelling) can have long-term negative effects, cautioning physicians, & encouraging medical researchers to identify alternative treatments.
Discuss specific examples of “non-oncology” drugs prescribed for co-morbidities such as hypertension or anxiety, may have unexpected effects on tumor growth, either directly or due e.g. to effects on the tumor.
Assess available treatments for patient comorbidities for their potential effects on tumor growth.
This is a one-day in person course designed to both inform clinical practice and to catalyze an important direction of research
This one-day meeting is focused on potential effects of drugs oncologists and internists administer for “non-oncology” purposes, i.e. to treat patients’ co-morbidities such as hypertension, diabetes, and cerebral edema etc.
“Non-oncology” drugs given to oncology patients may have
Drawing attention to the possibility of “unintended targets” of the “non-oncology drugs” has the potential to enable us to
Call for Abstracts:
Please send poster session abstracts to Dr. Lynn Caporale at caporale@usa.net.
